Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007273 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
A Phase 2 study of Cutaneous Sarcoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 3
- Study locations
NCT07007273 is a Phase 2 study of Cutaneous Sarcoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 17 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT07007273, a Phase 2 study of Cutaneous Sarcoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute IV infusion every 21 days (3 weeks).
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (3)
Florida
- Moffitt Cancer Center - Tampa
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2030-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07007273
The ClinicalTrials.gov registry entry for NCT07007273 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT07007273 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT07007273 about?
NCT07007273 is a clinical study titled "Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma". This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximate...
What is the current status of trial NCT07007273?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2025-06-20. Estimated completion is 2030-07.
What conditions does trial NCT07007273 study?
This clinical trial studies the following conditions: Cutaneous Sarcoma.
What interventions are being tested in trial NCT07007273?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT07007273?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007273 being conducted?
This trial has 3 study locations across Florida, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.